The reduced invasive potential of MDA/RLN2 transfectants in vitro suggested that the reduction in cellular motility through down-regulation of S100A4 was the dominant mechanism of relaxin's long-term effect on MDA-MB-231 breast cancer cells. Here, S100A4 is linked to breast cancer.